HUB Organoids can be developed directly from patient biopsies or resections with very high efficiency thanks to our technology, which has enabled us to generate a genetically stable, heterogeneous, and patient-relevant biobank from virtually all carcinomas. In addition, HUB Organoids can be generated from both normal and malignant patient tissues. Using HUB´s drug screening platform and unique models that represents the diverse mutational landscape present in cancer patients, clinically-relevant data can be generated that allow you to identify new targets, refine your drug combination strategies, or stratify your patient population with confidence.
To answer the need for a patient-relevant in vitro system to test new immunotherapies, we have recently developed a co-culture platform which uses our tumor organoid models in combination with either autologous or non-autologous PBMC or T cells. Additionally, co-cultures with other types of immune cells, including macrophages are currently under development.
The lack of preclinical cellular models that recapitulate the human disease is a major setback in the study of non-oncogenic conditions with an inflammatory component. HUB Organoid Technology is the only technology capable of generating in vitro models from non-transformed or non-malignant cells, which has allowed us to successfully establish organoid models and design specific assays to study conditions such as Inflammatory Bowel Disease (IBD), Crohn’s Disease, Ulcerative Colitis, and COPD.
Genetic diseases such as Cystic Fibrosis (CF), affecting both the lungs and gastrointestinal tract, or AAT, which affects the liver, have been difficult to study in the past due to the lack of genetically stable in vitro models or representative in vivo models. HUB Organoid Technology provides a major advance in this field as it allows to establish – in a matter of weeks – in vitro models derived directly from patient biopsies and preserving the original patient genetic make-up.
In the case of CF, we have been able to predict a patient’s clinical response (or lack of) using HUB Organoids™ as patient avatars to test multiple therapeutic strategies. Moreover, we have successfully generated a CF biobank which consists of more than 700 organoid models derived from rectal biopsies of CF patients and representing more than 100 clinically-relevant mutations, both common and rare. Our CF biobank can be used to evaluate in vitro the effectiveness of novel compounds on the CF population or on specific mutations.
The preclinical assessment of safety of newly developed compounds is notoriously difficult and currently available models, including in vivo models have proven to be unreliable. HUB Organoids™ established from healthy human intestine, colon, lung, liver, and kidney faithfully recapitulate the original tissue response to external stimuli, thus providing a patient-relevant system for studying your compound´s safety, toxicity, and ADME/PK profiles. Our liver organoids have been validated in proof-of-concept toxicology studies which compared them to human donor hepatocytes. Our organoid cultures are generated from different organ regions (e.g. several parts of the gastrointestinal tract) and can greatly contribute to replacing, refining, and reducing the need for animal usage, according to the 3Rs.
In addition to our human organoid collection, we have developed a collection of organoids derived from commonly used preclinical animal models such as mouse, rat, dog, and minipig.
Most traditional cell-based models lack patient-relevance and cell type-specific surface proteins that are recognised by viruses during an infection, therefore cannot be applied to virology studies. On the other hand, healthy HUB Organoids™ are suitable to studying infectious diseases such as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Respiratory Syncytial Virus (RSV), or Hepatitis B Virus (HBV) thanks to preserving normal surface protein expression.
As inventors of the HUB Organoid Technology and leading experts in patient-derived organoid development we can support your drug testing programs in therapeutic areas of high unmet need. By collaborating with us you will have the opportunity to leverage our state-of-the-art technology and extensive experience to develop new clinically relevant models.